Editorial draft — not for publication yet. Midazolam content needs clinical and legal review before publication. This is general information, not a legal decision about a product or action.

Quick answer

The manufacturer’s catalogue describes Mydlam-7.5 Tablet as containing midazolam BP 7.5 mg and lists a blister pack presentation. “Mydlam” is the product brand name in that catalogue; “midazolam” is the stated active ingredient. These details describe the manufacturer listing, not a way to verify a tablet or pack in someone’s possession.

For general active-ingredient information, read the Midazolam medicine guide.

Mydlam-7.5 is listed as a midazolam tablet

The product is listed by Albion Laboratories Limited in Bangladesh. Brand availability and authorisation are country-specific. A product marketed in one country should not be treated as a UK-authorised medicine merely because its active ingredient is also used in UK medicines.

Why formulation and route matter

Midazolam products are not interchangeable simply because they contain the same active ingredient. UK product information includes injection used by healthcare professionals for procedural sedation, anaesthesia and intensive-care sedation, and oromucosal products prescribed for specific seizure emergencies. Those routes, settings and uses are different from assuming a 7.5 mg tablet is a UK treatment for anxiety or sleep.

The product leaflet and prescription must match the exact medicine. Never convert a dose between tablets, liquid, injection or oromucosal syringes, and do not use a dose found online. A clinician determines whether a specific formulation is appropriate and what monitoring is required.

What the name can—and cannot—tell you

A product catalogue can identify what the manufacturer says it makes. It cannot confirm the contents or authenticity of a separate tablet, explain how it should be used for an individual, or prove UK supply status. If you need information about a pack, show it to a pharmacist rather than relying on photographs or online pill-identification pages.

If your question is about a UK midazolam medicine already prescribed to you or someone in your care, follow that product’s own patient leaflet and prescriber instructions. Buccal midazolam used in an individual seizure plan is not the same as taking a tablet for general sedation.

Need help in the UK? Call 999 for a life-threatening emergency. For urgent medical advice that is not an emergency, contact NHS 111. Ask a pharmacist or prescriber about your specific medicine.

Frequently asked questions

What is Mydlam 7.5?

Albion Laboratories Limited lists Mydlam-7.5 as a tablet containing midazolam BP 7.5 mg. This manufacturer information does not verify a particular pack or establish UK authorisation.

Is Mydlam the same as midazolam?

Mydlam-7.5 is listed by its manufacturer as a brand product containing midazolam. The name alone cannot verify the contents of an individual tablet, and product authorisations and formulations vary by country.

Is Mydlam 7.5 the same as Buccolam 7.5 mg?

No. The manufacturer lists Mydlam-7.5 as a tablet, while Buccolam 7.5 mg is a specific oromucosal liquid formulation in a pre-filled oral syringe. Do not substitute, compare or convert doses between products.

Sources and further reading

This draft draws on brand or manufacturer product information and UK sources below. Product information is market-specific; check the leaflet supplied with your exact product.

Editorial status: Editorial draft — clinical and regulatory review required before publication. Sources checked on 2 October 2026.

Related information

Read the Mydlam product overview or continue to another topic: